Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.51 |
| ▸ | GRM5 | P41594 | 11/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014227 | 1.00 | PDK4 (0.56) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL7831576 | 0.88 | PDK4 (0.58) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL22658966 | 0.88 | PDK4 (0.47) | PDK4NAMPTGRM1GRM5 | |
| SCHEMBL29407780 | 0.88 | PDK4 (0.47) | PDK4NAMPTGRM1GRM5 | |
| SCHEMBL1364792 | 0.87 | PDK4 (0.57) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL2811392 | 0.87 | PDK4 (0.60) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL29914645 | 0.87 | PDK4 (0.57) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL578028 | 0.86 | NAMPT (0.60) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL25378040 | 0.86 | PDK4 (0.48) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL30582019 | 0.86 | PDK4 (0.48) | PDK4NAMPTGRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368263-B | Synthesis and pharmaceutical application of cinnamic acid amide derivative | 南开大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-115368263-A | Synthesis of cinnamic acid amide derivative and pharmaceutical application thereof | 南开大学 | 2022-11-22 | — | — | CN | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| EP-2489663-A1 | Compounds as syk kinase inhibitors | Almirall, S.A. (ES) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| EP-1689712-B1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | PDK4 362/4885NAMPT 3894/4885GRM1 3064/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | PDK4 299/4885NAMPT 3783/4885GRM1 3588/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | PDK4 299/4885NAMPT 3783/4885GRM1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.